MiR‐34a resensitizes colon cancer cells to 5-FU, miR-329-3p sensitizes osteosarcoma cells to cisplatin, miR-7 sensitizes gastric cancer cells to cisplatin all via LDHA inhibition. Here, LDHA is linked to gastric cancer.